Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Holdings Boosted by Federated Hermes Inc.

Federated Hermes Inc. grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 76.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 212,768 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,911 shares during the period. Federated Hermes Inc.’s holdings in Collegium Pharmaceutical were worth $6,549,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Collegium Pharmaceutical by 28.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company’s stock valued at $272,000 after acquiring an additional 1,967 shares during the last quarter. Everence Capital Management Inc. acquired a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at $302,000. Cornercap Investment Counsel Inc. lifted its holdings in shares of Collegium Pharmaceutical by 4.6% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 22,002 shares of the specialty pharmaceutical company’s stock valued at $677,000 after purchasing an additional 959 shares in the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at $502,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Collegium Pharmaceutical by 10.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 45,862 shares of the specialty pharmaceutical company’s stock valued at $1,412,000 after purchasing an additional 4,192 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have recently issued reports on COLL. Needham & Company LLC restated a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. StockNews.com upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Jefferies Financial Group restated a “hold” rating and issued a $37.00 target price (up previously from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Piper Sandler restated an “overweight” rating and issued a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, Truist Financial increased their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Trading Up 1.0 %

Collegium Pharmaceutical stock opened at $35.84 on Friday. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 30.37 and a beta of 1.03. Collegium Pharmaceutical, Inc. has a one year low of $20.83 and a one year high of $40.95. The company’s fifty day moving average price is $37.06 and its two-hundred day moving average price is $31.18.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million for the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.